Aligos Therapeutics presented positive data from eight presentations at the European Association for the Study of the Liver (EASL) Congress 2025. Updated 96-week data for ALG-000184 monotherapy showed all subjects in both HBeAg-positive and HBeAg-negative cohorts achieved HBV DNA viral suppression below the lower limit of quantification (10 IU/mL). Specifically, 100% of HBeAg-positive subjects (9/9) achieved this at Week 96, with 5 of 9 further achieving HBV DNA below the lower limit of detection.
All 11 HBeAg-negative subjects demonstrated rapid and sustained HBV DNA suppression by Week 24, maintained for up to 96 weeks, with 8 of 8 subjects achieving HBV DNA below the lower limit of detection at Week 96. No viral breakthrough or known CAM resistant mutations were identified. Concurrent multi-log reductions in HBV antigens suggest potential inhibition of cccDNA establishment.
For ALG-055009, new data demonstrated substantial, dose-dependent reductions in liver fat across all key subgroups, including GLP-1 receptor agonist users. Statistically significant improvements in atherogenic lipids, such as lipoprotein (a), were also achieved, suggesting an added benefit for patients at risk for cardiovascular disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.